Document 2358
 DOCN  M94A2358
 TI    Disease progression and survival among HIV-infected injecting drug users
       (IDUs) by enrollment in drug abuse.
 DT    9412
 AU    Brown LS; John S; Neaton JD; Wentworth D; Stanley Addiction Research &
       Treatment Corp., Brooklyn, NY.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):322 (abstract no. PC0219). Unique
       Identifier : AIDSLINE ICA10/94370217
 AB    OBJECTIVES: To compare HIV-infected disease progression and survival
       according to enrollment in drug abuse treatment among HIV-infected IDUs.
       METHODS: Eight hundred thirty one (831) HIV-infected IDUs provided data
       on demographic, clinical, and drug abuse-related information. Data was
       collected at study entry and at follow-up intervals of six months or
       less. Using a proportional hazards regression model, we calculated
       relative risks (RR) (drug treatment program: yes vs no) stratified by
       clinical center with covariates of CD4 count, age, race, karnofsky score
       disease progression history, and use of anti-retroviral therapy and PCP
       prophylaxis. RESULTS: Of the 831 IDUs in this study, 47% (394) were
       enrolled in drug abuse treatment at the time of entry in this clinical
       trial network. At study entry, IDU's enrolled in drug abuse treatment
       were likely to be Black or Latino (83% vs 61%) and female (37% vs 24%),
       and less likely to report a prior opportunistic infection or malignancy
       (19% vs 35%) or the use of PCp prophylaxis (27% vs 51%) as compared to
       IDUs not enrolled in drug abuse treatment. The overall adjusted RR (drug
       treatment enrollment: yes vs no) was 1.40 (95% CI: 0.83-2.35) for
       bacterial pneumonia, 1.8 (95% CI: 0.79-4.3) for tuberculosis, 0.95 (95%
       CI: 0.7-1.29) for disease progression, and 0.90 (95% CI: 0.59-1.37) for
       death. CONCLUSION: This study suggests that enrollment in drug abuse
       treatment may have no role in delaying HIV disease progression.
 DE    AIDS-Related Opportunistic Infections  Comparative Study  Female  Human
       HIV Infections/COMPLICATIONS/IMMUNOLOGY/*MORTALITY  Karnofsky
       Performance Status  Leukocyte Count  Male  Neoplasms/COMPLICATIONS
       Proportional Hazards Models  Risk Factors  Substance Abuse,
       Intravenous/*COMPLICATIONS/THERAPY  T4 Lymphocytes  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).